A detailed history of Privium Fund Management B.V. transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Privium Fund Management B.V. holds 5,580,725 shares of PRQR stock, worth $10 Million. This represents 2.62% of its overall portfolio holdings.

Number of Shares
5,580,725
Previous 5,344,446 4.42%
Holding current value
$10 Million
Previous $12.2 Million 24.3%
% of portfolio
2.62%
Previous 3.62%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$1.65 - $2.39 $389,860 - $564,706
236,279 Added 4.42%
5,580,725 $9.26 Million
Q2 2022

Jul 28, 2022

BUY
$0.56 - $1.0 $56,000 - $100,000
100,000 Added 1.91%
5,344,446 $4.16 Million
Q1 2022

May 10, 2022

BUY
$0.9 - $8.39 $430,908 - $4.02 Million
478,787 Added 10.05%
5,244,446 $4.75 Million
Q4 2021

Feb 09, 2022

BUY
$6.58 - $8.44 $31.4 Million - $40.2 Million
4,765,659 New
4,765,659 $38.9 Million

Others Institutions Holding PRQR

About ProQR Therapeutics N.V.


  • Ticker PRQR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,362,096
  • Market Cap $128M
  • Description
  • ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...
More about PRQR
Track This Portfolio

Track Privium Fund Management B.V. Portfolio

Follow Privium Fund Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Privium Fund Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Privium Fund Management B.V. with notifications on news.